Methotrexate topical - NanoCyte
Alternative Names: IR methotrexate - NanoCyteLatest Information Update: 21 Jan 2022
At a glance
- Originator NanoCyte
- Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Psoriasis in Israel (Topical)
- 31 Mar 2011 Preclinical development is ongoing in Israel
- 23 Aug 2004 Preclinical trials in Psoriasis in Israel (Topical)